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Abstract A fusion between the EML4 (echinoderm
microtubule-associated protein-like) and ALK (anaplastic
lymphoma kinase) genes was identified in non-small cell
lung cancer (NSCLC) in 2007 and there has been rapid
progress in applying this knowledge to the benefit of
patients. However, we have a poor understanding of EML4
and ALK biology and there are many challenges to
devising the optimal strategy for treating EML4-ALK
NSCLC patients. In this review, we describe the biology of
EML4 and ALK, explain the main features of EML4-ALK
fusion proteins and outline the therapies that target EML4-
ALK. In particular, we highlight the recent advances in our
understanding of the structures of EML proteins, describe
the molecular mechanisms of resistance to ALK inhibitors
and assess current thinking about combinations of ALK
drugs with inhibitors that target other kinases or Hsp90.
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Background
Lung cancer accounts for around 13 % of all cancers
diagnosed worldwide, and accounts for around 1.3 million
deaths per year [1]. The most common morphological
subtype is lung adenocarcinoma, which is now known to
comprise a genomically diverse mosaic of molecular
defined subtypes defined by the presence of somatic
mutations in so-called driver oncogenes [2]. The proto-
typical somatic activating mutation in EGFR launched the
paradigm shift in personalised medicine for lung adeno-
carcinoma, [3–5].
Most NSCLC patients are treated with cytotoxic
chemotherapy using a DNA-binding drug such as carbo-
platin/cisplatin in combination with a topoisomerase type II
inhibitor such as etoposide or an anti-mitotic such
as vinorelbine. Standard treatment also includes
immunotherapies that target angiogenesis. Genetic analysis
of lung cancers has revealed their underlying complexity,
with many different driver mutations that are mutually
exclusive in most cases. Molecular subtyping is now rou-
tine in NSCLC and patients with an EGFR mutation are
treated with an appropriate tyrosine kinase inhibitor (TKI)
such as erlotinib in first line therapy. Another reasonably
common mutation identified in two landmark studies in
2007 was the first somatic oncogenic gene translocation in
lung cancer, involving fusion of two genes, EML4
(echinoderm microtubule associated protein-like 4) and
ALK (anaplastic lymphoma kinase) [6, 7]. The identifica-
tion of EML4-ALK in 4–6 % of lung adenocarcinomas led
to the second major clinical development in personalised
therapy in NSCLC [8, 9]. Current drug development on
EGFR and EML4-ALK have advanced beyond initial
therapy, to rational effective treatment upon development
of resistance [10, 11]. Efficacy has been demonstrated for
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kinase inhibitors targeting other rare mutations such as the
ROS translocation and BRAF V600E mutation [12, 13].
Molecular and cellular biology of EML4-ALK
fusions
EML4
Sea urchin EMAP (echinoderm microtubule-associated
protein) was the first member of the EML family of pro-
teins to be identified [14]. Subsequently, further EML
proteins were found in vertebrates, worms and insects [15].
At the level of primary sequence, the defining feature of
EML proteins is the presence of a HELP (hydrophobic
EMAP-Like protein) motif N-terminal to a number of WD
(Trp-Asp) repeats (Fig. 1a) [16]. The six human EML
proteins fall into two classes, based on domain organisa-
tion: EML1-4 have an N-terminal coiled-coil region
separated from the C-terminal HELP-WD region by a
linker region that is rich in Ser, Thr and basic residues,
whereas EML5 and EML6 consist of three copies of the
HELP-WD region with no coiled-coil.
Recent structural studies have established the molecular
architecture of this family of proteins (Fig. 1b). Crystal
structures of the coiled-coil regions of human EML2 and
EML4 revealed trimeric self-association, and this region was
termed the trimerisation domain (TD) [17]. Interestingly,
several splice variants of EML2 lack the coiled-coil, resulting
in a presumably monomeric protein isoform. The crystal
structure of the EML1 HELP-WD region revealed a pair of
intimately associated b-propellers [18]. Individual WD40
repeats form a 4-stranded b-sheet that fit together as the
individual blades of a propeller structure. Most structures of
WD repeat-containing b-propellers are formed from seven
blades, but other types occur and the primary sequences of
some individual blades do not fit theWD consensus [19]. Due
to the uncertainty in predicting WD repeats, the arrangement
of two propellers in tandem found in EML1 was unexpected
and, atypically, the C-terminal propeller incorporates a blade
unrelated to WD40 repeats in both sequence and structure.
Moreover, this atypical blade is formed from two sub-do-
mains that originate from distant regions in the primary
sequence (coloured orange and dark teal in Fig. 1b). These
features of the structure led us to name this novel structure the
TAPE (Tandem Atypical Propeller EML) domain.
Fig. 1 Overview of EML proteins. a Domain structure of human
EML4 with structural features labelled. Primary (1) sequence
features are labelled in black: CC, coiled-coil; basic region; HELP,
Hydrophobic motif found in EML proteins; WD repeats, Trp-Asp
repeats. Tertiary (3) structure features are labelled in red text: TD,
trimerisation domain; TAPE, tandem atypical propeller domain found
in EML proteins. The TAPE domain N-terminal region is coloured
teal and the C-terminal region is coloured orange. b Speculative
model of the overall trimeric architecture of the EML4 protein.
Crystal structures of the EML4 TD (PDB code 4CGC [17]) and
EML1 TAPE domain (PDB code 4CI8 [18]) are connected with
dotted lines to show the basic region that is predicted to be
unstructured. One protomer of the trimer is coloured using the
scheme in 1a—this shows how the N- and C-terminal regions of the
TAPE domain (teal and orange, respectively) come together to close
the fold of this domain
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EML proteins interact with soluble tubulin and micro-
tubules, and a functional association with the mitotic
spindle has been shown for several family members [16,
18, 20–23]. Although the HELP motif has been described
as a microtubule-binding domain, the crystal structure of
EML1 shows that this is not possible because the motif is
buried in the interface of the two propellers [18]. In fact,
the basic region and TD are necessary and sufficient for
microtubule association in the context of EML proteins
[17]. Conversely, an intact TAPE domain has the capacity
to associate with soluble tubulin. EML4 is expressed in a
wide range of tissues, including the lung, and may there-
fore have a housekeeping role in the formation or
maintenance of microtubules [24].
ALK
ALK is a member of the insulin receptor kinase super-
family, a large grouping which includes other tyrosine
kinases of relevance to cancer such as MET and RON [25–
28]. ALK was first identified as a fusion partner with
nucleophosmin (NPM) in a chromosomal translocation
found in non-Hodgkin’s lymphoma, resulting in constitu-
tive kinase activity [29, 30]. ALK is a 1620aa protein with
a domain composition that comprises only a few conserved
domains interspersed with low complexity sequence that is
predicted to be disordered (Fig. 2a). In common with other
receptor tyrosine kinases, ALK has a transmembrane (TM)
helix and a cytoplasmic TK domain. The extracellular
region includes two MAM (Meprin, A5 protein and protein
tyrosine phosphatase Mu) domains, one on either side of a
LDLa (Low-density lipoprotein receptor domain class A)
domain, all of which are N-terminal to a Gly-rich region
that precedes the TM helix. The structure of the TK domain
has been resolved using X-ray crystallography, but there
are currently no structures of the other domains of ALK
[31, 32].
Based on its expression pattern, ALK most likely con-
tributes to the development of the nervous system [33, 34].
Knockout mice are viable and show no gross defects but
have behavioural abnormalities [35, 36]. Activating ligands
of ALK in model organisms such asD. melanogaster and C.
elegans have been identified and the contribution of ALK to
the development of specific tissues has been elucidated
[37]. For example, in Drosophila, the secreted protein
ligand jelly belly (Jeb) activates Alk kinase in synaptoge-
nesis and the organisation of muscle tissue [38–40]. The
identification of activating ALK ligands in humans is
inconclusive and although pleiotrophin (PTN) and midkine
(MK) have been proposed [41–43]; there is no consensus on
whether these are bone fide activators of ALK [37, 44].
Inarguably, the pathways through which mutant ALK
mediates oncogenesis are more comprehensively explored.
ALK signalling is activated in cancer cells through three
principal mechanisms: gene fusion events, such as NPM-
ALK and EML4-ALK; ALK gene amplification; and
activating point mutations such as F1174L in neuroblas-
toma (Fig. 2b). The wider picture of ALK activation has
been expertly reviewed elsewhere [37]. In ALK fusions,
the partner drives ALK activity at the level of gene
expression and through multimerisation of the ALK
kinase domain, which is presumed to promote
Fig. 2 Overview of ALK. a Domain structure of ALK with structural
features labelled: MAM, Meprin, A5 protein and protein tyrosine
phosphatase Mu domain; LDLa, Low-density lipoprotein receptor
domain class A; G-rich, glycrine-rich region; TM, transmembrane
helix; TK, tyrosine kinase domain. The interactions of upstream,
extracellular signalling molecules with ALK are shown: pleiotrophin
(PTN) and midkine (MK) as putative ligands in humans; jelly belly
(Jeb) as a confirmed ligand in Drosophila. b Outline of oncogenic
ALK signalling mechanisms. Crystal structure of ALK TK domain
(PDB code 3LCT [32]) is shown as a cartoon representation, coloured
magenta
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autophosphorylation. Furthermore, the partner determines
the sub-cellular localisation of the fusion protein. The
oncogenic potential of ALK fusions has been demonstrated
in cell and animal model systems [7, 45–47].
The pathways through which ALK mediates oncogene-
sis have been extensively explored in the case of NPM-
ALK (reviewed by [37, 48]). NPM-ALK activation signals
through multiple pathways, including RAS/ERK, PLCc
[46], PI3 K/AKT, and JAK/STAT [49]. These confer
neoplastic phenotype, cell proliferation, cell survival and
changes in cytoskeleton. In contrast to the extensive studies
on NPM-ALK, there has been relatively little experimental
validation of signalling pathways mediated by EML4-
ALK, which has been done mainly through the use of ALK
inhibitors in cell lines derived from NSCLC patients and
model cell lines expressing recombinant EML4-ALK.
Molecular genetics of EML4-ALK patients
The EML4 and ALK genes are oriented in opposite direc-
tions within the short arm of chromosome 2, and the EML4-
ALK fusion gene arises through a paracentric inversion of
this region [inv(2)(p21p23)] (Fig. 3a) [7]. In all cases, the
breakpoint within the ALK gene lies close to the 50 end of
exon 20. Thus, the entire extracellular domain and TM helix
are excluded from the EML4-ALK fusion, which just
incorporates the cytoplasmic portion of ALK including the
TK domain. The fusion points within the EML4 gene are
more variable. The most common variants end at exon 13
(v1), exon 20 (v2) and exon 6 (v3) [7, 50, 51]. At least
fifteen variants have been identified, the shortest of which,
v5, includes just exons 1 and 2 of EML4 (Table 1).
Both v3 and v5 exist as a mixture of two isoforms
generated by alternative splicing [51–53]. These variants of
EML4-ALK fusion proteins all have a TD, which is
essential for ALK autophosphorylation and activation.
Most variants have the basic region and many have a
variable portion of the TAPE domain (Fig. 3b). The pres-
ence of incomplete protein domains in some EML4-ALK
variant proteins is unusual because oncogenic gene fusion
proteins normally incorporate only intact domains con-
nected by linker regions [54]. This feature has
consequences for the biology of EML4-ALK fusion pro-
teins, their molecular properties, the pathways through
which they signal and potential therapeutic approaches.
EML4-ALK cell lines and signalling
Cell lines harbouring EML4-ALK fusions were established
from NSCLC patients [51, 55]. Variant 1 was detected in
H3122, DFCI024 and STE-1 cell lines, whereas variant 3a/
b was found in the H2228 cell line. These cell lines have
formed the basis for most of the studies on the signalling
pathways downstream of EML4-ALK, EML4-ALK drives
the phosphorylation of Akt and ERK, which are reduced
upon ALK inhibition (TAE684) in H2228 and H3122 cell
lines [51, 56, 57]. EML4-ALK is upstream of ERK in Ba/
F3 cell lines expressing EML4-ALK fusions, but does not
seem to influence Akt in this system [58]. Ba/F3 is a
murine pro-B cell line that depends on IL-3 for cell growth
and this dependency is overcome when certain oncogenes
are expressed, such as EGFR and EML4-ALK [7, 59, 60].
EML4-ALK may also be upstream of STAT3 phosphory-
lation; however, there is no clear consensus among reports.
While some studies show a clear reduction in STAT3
phosphorylation upon TAE684 treatment [57, 61], other
studies show a minimal effect of TAE684 on STAT3
phosphorylation in H2228 and H3122 [51].
There are differences in sensitivity towards ALK inhi-
bitors between EML4-ALK variants. For example, the
growth of H3122 cells is sensitive to TAE-684, whereas
H2228 and DFCI032 are only a little more sensitive than
controls (A549—KRAS G12S, PC-9—EGFR del E746-
750) [51]; however, other groups found that both H3122
and H2228 cells are sensitive to TAE-684 [57] or that
while TAE684 has a cytotoxic effect on H3122, there is a
cytostatic effect on H2228 [56]. Upon addition of TAE-
684, EML4-ALK phosphorylation is ablated in all three
cell lines harbouring the fusions, however, the conse-
quences for downstream signalling pathways are divergent:
p-Akt and p-ERK are reduced in H2228 and H3122, but
these phosphorylation signals are lost entirely only in the
H3122, which exhibit PARP cleavage and apoptosis [56,
61]. In contrast, inhibition of ALK alone is not sufficient to
induce significant apoptosis in H2228 cells. Using the Ba/
F3 model, sensitivity of variants to two chemically-distinct
inhibitors (TAE684 and crizotinib) showed a similar pat-
tern—v2 most sensitive, v1 and v3b intermediate and v3a
least sensitive, covering a GI50 range from 0.15 to 1 lM
[58]. This was not due to differences in potency for the
variants, but differential downstream responses, notably in
ERK phosphorylation. Finally, ALK inhibition destabilised
the fusion proteins but to differing degrees in that v2 and,
to a lesser extent, v1 are destabilised by ALK inhibitor,
whereas this effect is less clear in v3a [58].
ALK activation is driven by the TD of EML4, which
drives self-association of the kinase domains. The TAPE
domain is not critical for ALK activation because deletion
within the TD and basic regions (aa31-140) of EML4-ALK
v1 reduced kinase activity and transforming activity, but
deletions within the TAPE domain had little or no effect
[7]. Indeed, EML4-ALK v5, which incorporates the
shortest portion of EML4 of any fusion and lacks any of the
TAPE domain, also has kinase and transforming activity.
Whilst the TD domain could drive autophosphorylation
following self-association of the kinase domain, the
1212 R. Bayliss et al.
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mechanism by which ALK is activated by the TD is
unknown and it is unclear how it might differ from ALK
fusions in which the partner is dimeric. In addition, from a
structural biology point of view, it seems likely that the
mechanistic details of ALK activation might be influenced
by the presence of portions of the TAPE domain.
The intracellular localisation of the most common
EML4-ALK variant proteins has been studied in model cell
lines and in cancer cells derived from patients. Using
recombinant proteins expressed in NIH3T3 cells, EML4-
ALK v1 and v2 were localised to the cytoplasm, whereas
v3 localised to the nucleus, using an ALK antibody to label
the fusion proteins [58]. YFP-fusions of EML4-ALK v1,
v2 and v5a expressed in HeLa had a diffuse, cytoplasmic
localisation, whereas v3a co-localised with microtubules in
the cytoplasm [17]. Consistent with the localisation of the
recombinant proteins, endogenous EML4-ALK v1 was
diffusely localised in the cytoplasm in H3122 cells and
endogenous EML4-ALK v3a co-localised with
microtubules in H2228 cells [17]. Independent studies of
the localisation of endogenous EML4-ALK v1 to the
cytoplasm of H3122 and STE-1 cells showed a more dis-
crete pattern of ALK puncta, described as an unidentified
intracellular compartment [62]. It appears that the majority
of EML4-ALK fusion protein variants do not associate
strongly with microtubules, despite having the basic region
and TD of EML4. Further studies are required to investi-
gate the localisation of EML4-ALK fusions at higher
resolution and to clarify whether microtubule association is
relevant to ALK signalling, as is the case for other RTK
fusions with microtubule binding proteins [63].
EML4-ALK patients and their treatment
NSCLC patients harbouring EML4-ALK or EGFR muta-
tions are younger, have more advanced disease and are
more likely to be non-smokers or light smokers than the
Fig. 3 Overview of EML4-ALK fusions and variants. a EML4-ALK
fusion gene is generated by a paracentric inversion on the short arm of
chromosome 2. Dotted lines indicate potential fusion sites.
b Schematic illustrations of four major EML4-ALK variant proteins,
showing where the ALK TK domain is inserted into the EML4
protein. c The individual subdomains that make up the TAPE domain
of EML4 are shown. The two propellers of the TAPE domain have
thirteen canonical blades and a non-canonical blade comprising the
12N and 12C subdomains. The positions of ALK TK domain
insertion into the EML4 structure are shown as black squares,
labelled with the variant number. Note that, with the exception of v3
and v5, all variants have ALK inserted into the TAPE domain
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average [53]. Furthermore, EML4-ALK fusions are more
common in lung adenocarcinoma than other NSCLCs [64].
NSCLC patients with EGFR mutations show a markedly
improved response when treated with TKIs such as
gefitinib, with a doubling of the time to progression (TTP)
and greater than 50 % increase in overall survival [4, 65].
EML4-ALK NSCLC patients do not generally have EGFR
mutations or indeed any other key driver mutations, such as
Table 1 List of EML4-ALK variants
EML4-ALK
variant
Gene fusion
points
Mutation
frequency1
Cell lines Structural features References
V1 E13;A20 33 % (25 %) H3122,
DFCI032,
STE-1
EML4- TD, basic, HELP motif, incomplete TAPE
ALK TK
[7, 6, 51, 55]
V2 E20;A20 9 % (7.5 %) EML4- TD, basic, HELP motif, incomplete TAPE
ALK TK
[7, 51]
E20;ins18A20 (\1 %) EML4- TD, basic, HELP motif, incomplete TAPE
ALK TK
[108]
V3a E6a;A20 29 % (18.5 %)2 H2228 EML4- TD, basic
No HELP or TAPE
ALK TK
[51]
V3b E6b;A20 29 % (18.5 %)2 H2228 EML4- TD, basic
No HELP or TAPE
ALK TK
[6, 51]
V4 E15del60;del71A20 2 % (\1 %) EML4- TD, basic, HELP motif, incomplete TAPE
ALK TK
[51]
V40 E14;ins11del49A20 3 % (\1 %)3,5 EML4- TD, basic, HELP motif, incomplete TAPE
ALK TK
[52]
V5a E2;A20 2 % (\1 %)4 EML4- TD
No basic, HELP or TAPE
ALK TK
[52]
V5b E2;ins117A20 (\1 %) EML4- TD
No basic, HELP or TAPE
ALK TK
[52]
V50 E18;A20 2 % (\1 %) EML4- TD, basic, HELP motif, incomplete TAPE
ALK TK
[109]
V6 E13;ins69A20 (\1 %) EML4- TD, basic, HELP motif, incomplete TAPE
ALK TK
[110]
V7 E14;del12A20 See V40 (\1 %)3,5 EML4- TD, basic, HELP motif, incomplete TAPE
ALK TK
[110]
V8a E17;ins30A20 (\1 %)6 EML4- TD, basic, HELP motif, incomplete TAPE
No functional ALK domain
[111]
V8b E17ins61;ins34A20 (\1 %)6 EML4- TD, basic, HELP motif, incomplete TAPE
ALK TK
[111]
E17;ins68A20 1 % (\1 %)6 EML4- TD, basic, HELP motif, incomplete TAPE
ALK TK
[108]
Unknown 19 % (45 %)
1 Mutation frequency obtained from [53] and COSMIC (Catalogue of somatic mutations in cancer), shown in parentheses [112]
2 Note that frequency of V3a and V3b are the same because they are splice variants
3 Note that V40 and V7 are combined in the source Ref. [53]
4 Note that V5a and V5b are combined in the source Ref. [53]
5 Note that COSMIC lists E14;A20 translocations, but not V40 and V7
6 Note that COSMIC lists E17;A20 translocations, but not V8a or V8b
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RAS [7, 65, 66]. There are of course exceptions: recent
reports described an EML4-ALK patient lacking EGFR
mutation who responded to erlotinib [67], and a patient
who harboured both EML4-ALK and EGFR mutations [68]
potentially reflecting intratumour genomic heterogeneity
which may in some cancers be considerable [69]. There
have been intensive efforts to develop ALK TKIs, and
EML4-ALK patients receiving them exhibit superior
response rates and disease control compared with
chemotherapy [9].
ALK inhibitors
The first research papers on EML4-ALK used non-specific
inhibitors such as WHI-P154 [7] or TAE684 [51]
(Fig. 4a). However, the first clinical studies used crizo-
tinib, a selective ALK/MET/ROS ATP-competitive TKI
that is orally available and was evaluated in patients with
advanced solid tumours (Fig. 4b) [65]. EML4-ALK
NSCLC patients showed clear responses, and an expanded
trial (PROFILE 1001) was established that focussed on
EML4-ALK patients. The results of this trial were posi-
tive, with over 60 % overall response rate, leading to a
phase II trial (PROFILE 1005) with a similar rate of
response. On the basis of these trials, crizotinib was
approved by the FDA in 2011 for the first-line treatment of
advanced NSCLC in patients with ALK? tumours. In
other countries, there have been concerns over the cost of
treatment relative to the benefit and in the UK crizotinib is
available to patients in the UK through the cancer drugs
fund. A further clinical study compared the efficacy of
crizotinib to additional chemotherapy (docetaxel or
pemetrexed) in patients who had already undergone one
round of platinum-based chemotherapy (PROFILE 1007).
Crizotinib was better in terms of progression-free survival
and overall response rate, but not in overall survival.
Initial results from an ongoing phase III trial in a first-in-
line setting shows that crizotinib is superior to
chemotherapy (PROFILE 1014) in terms of progression-
free survival and overall response rate, but it is too early to
know whether there is a significant difference in terms of
overall survival [70].
Many of the available ATP competitive ALK inhibitors,
including the clinically approved drugs and those under
investigation, are based on three chemical scaffolds
(Fig. 4a–c)—aminopyridine (crizotinib and PF-06463922)
[71, 72], diaminopyrimidine (TAE684, ceritinib, brigatinib,
KRCA-0080) [73, 74] and the unusual dihydrobenzocar-
bazole (alectinib) [75]. PF-06463922, an ATP-competitive
ALK/ROS1 inhibitor is a macrocyclic compound, based on
stabilization of the closed conformation of crizotinib bound
to ALK that was observed in the crystal structure (Fig. 4b,
d) [72].
Mechanisms of resistance to ALK TKIs
EML4-ALK patients who initially respond to TKIs such as
crizotinib inevitably relapse as the tumour acquires resis-
tance to the drug. Many different resistance mechanisms
have been identified, the most common of which is alter-
ations in the EML4-ALK gene, which occurs in
approximately a third of patients. These alterations are
primarily EML4-ALK gene amplification, mutations
within the TK domain of ALK (Table 2), or sometimes
both [76–80]. Another frequently documented drug resis-
tance mechanism is upregulation of alternative RTKs, such
as EGFR, KIT, IGF-1R and SRC, to activate bypass
pathways [55, 77–79, 81]. However, these mechanisms do
not account for all drug resistance. To address this shortfall
in our knowledge, a recent study screened 12,800 human
ORFs to identify genes that confer resistance to crizotinib
or TAE684 in H3122 cells [82]. The screen identified a
diverse selection of 54 genes, including kinases, growth
factors, scaffolding proteins and DNA-associated proteins,
half of which were able to drive ERK and/or AKT activity.
Among the genes were P2 purinergic receptors of the P2Y
subfamily, which activate protein kinase C (PKC) to
mediate resistance to crizotinib [82]. The major effort to
identify and characterise drug resistance pathways that
bypass ALK and to develop strategies for overcoming
resistance in patients will continue. However, at present,
there is more substantial progress in addressing the chal-
lenge of ALK-dependent drug resistance mechanisms.
Drug-resistant mutations in the ALK TK domain cluster
around the ATP binding site and enhance ATP binding,
reduce crizotinib binding or both (Fig. 4d; Table 2) [80].
The most common mutation is residue Leu1196 to
methionine [78, 83, 84]. Leu1196, sometimes referred to as
the gatekeeper, lies at the back of the active site and forms
extensive interactions with crizotinib. The mutation dis-
rupts these interactions, weakening the potency of
crizotinib [76]. The gatekeeper position in the active site is
frequently the site of drug-resistant mutations in other
tyrosine kinases, such as T315I in ABL and T790M in
EGFR that disrupt drug interactions and help to activate the
kinase [85]. Acquired drug-resistant mutations are also
observed in Phe1174, which is the site of driver mutations
in ALK in neuroblastoma [86]. One route to overcoming
drug resistance is to use an alternative drug that is more
potent against mutant ALK. Indeed, a subset of the muta-
tions that desensitize ALK to crizotinib retain sensitivity to
the second-generation ALK inhibitors alectinib and cere-
tinib (Table 2). However, the 1151Tins and G1202R
mutations confer resistance to all second-generation
inhibitors.
The macrocylic inhibitor PF-06463922 is more potent
against WT ALK and ALK mutants than crizotinib and
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retains substantial activity against ALK mutants that are
resistant to crizotinib and second-generation inhibitors
[87]. Although activity against G1202R ALK is lower than
WT (77 nM IC50 vs 1.3 nM IC50), this is similar to the
potency of crizotinib against WT ALK [72]. Furthermore,
PF-06463922 is active against alectinib-resistant cell lines
harbouring the I1171T or V1180L mutant, and ceretinib-
resistant cell lines harbouring G1202R [87]. PF-06463922
elicits a durable response in mouse xenograft models of
EML4-ALK NSCLC, based on H3122 cell lines harbouring
WT ALK or crizotinib-resistant mutants L1196 M and
G1269A, and the compound induces tumour regression in
mice bearing tumours that relapsed on crizotinib. Brain
metastasis is the first step in disease progression in up to
50 % of NSCLC EML4-ALK patients being treated with
crizotinib [88]. Importantly, PF-06463922 is predicted to
cross the blood–brain barrier in humans, and is active
against an NSCLC brain metastasis model using intracra-
nial xenografts of WT or L1196M ALK H3122 cells [87].
This is an improvement over crizotinib, which has limited
CNS penetration, and the brain is the most common site of
relapse of patients treated with crizotinib [89]. Ceretinib
also has brain penetration and is approved in patients who
have developed resistance to crizotinib [90].
Fig. 4 ALK tyrosine kinase inhibitors. Chemical structures of ALK
TKIs are shown with the core scaffold highlighted in red. a di-
aminopyrimidine. b Aminopyridine. c Dihydrobenzocarbazole.
d Crystal structure of ALK TK domain (pink cartoon) bound to
crizotinib (beige spheres). The image is based on PDB code 2XP2
[71]. Key residues mutated in drug resistance ALK are shown as
sticks, coloured teal
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The development of ATP-competitive inhibitors has
improved outcomes for patients and there is scope for
further improvements using the newest ALK inhibitors. It
is, however, inevitable that drug resistance will emerge for
these compounds and alternative strategies are under
investigation that could be applied as second-line to or in
combination with ALK inhibitors.
Hsp90 inhibitors
Molecular chaperones are a structurally diverse group of
proteins that function in protein folding and quality control
[91, 92]. Hsp90 is an ATP-dependent chaperone that sta-
bilises a wide variety of client proteins, including many
proteins that function in cancer-relevant pathways [93].
Geldanamycin and radicicol, both natural product inhibi-
tors of Hsp90, suppress oncogenic transformation but are
too unstable to be used clinically [94, 95]. More
stable derivatives of geldanamycin, such as 17-AAG,
17-DMAG and IPI-504 and synthetic Hsp90 inhibitors,
such as NVP-AUY922 and ganetespib, have been devel-
oped and tested clinically in a number of cancers [93, 96,
97]. These inhibitors act by blocking the ATP binding site
of Hsp90 and halting the ATPase cycle [91, 98, 99].
The first evidence that Hsp90 inhibitors might be useful
in EML4-ALK patients came from a phase II study that
assessed the efficacy of IPI-504 after EGFR TKI therapy in
patients with advanced NSCLC [100]. Although there was
a low response rate among patients with EGFR mutations,
strikingly, all three patients harbouring EML4-ALK
fusions responded, two with partial response and one with
stable disease over 7.2 months. EML4-ALK NSCLC cell
lines H3122 and MGH006 (variant unpublished) were
more sensitive to Hsp90 inhibition than EGFR mutant cell
lines, and the fusion protein was destabilized upon Hsp90
inhibitor treatment. This work was followed up in further
studies that showed EML4-ALK to be among the most
sensitive Hsp90 client proteins and crizotinib-resistant
H3122 (CR) (crizotinib-resistant) cells retained sensitivity
to Hsp90 inhibition [101, 102]. More recently, ganetespib
was shown to be effective at reducing tumour growth in
mice bearing H3122 cell xenografts, by*80 to 90 % after
33 days post-implantation [103]. This raises the question of
why EML4-ALK is so sensitive to Hsp90 inhibition, and
how this property might be exploited in treatment.
Not all EML4-ALK fusion variants are equally sensitive
to Hsp90 inhibition as v1 and v2 but not v3a were found to
be sensitive to 17-DMAG [58]. Furthermore, artificial
EML4-ALK fusions based on v2 lacking additional one
additional WD repeat was equally sensitive to 17-DMAG,
but removing 5 WD repeats or the entire HELP-WD region
gave rise to fusions that are as stable as control cells [58]. It
was concluded that the molecular basis of EML4-ALK
sensitivity to Hsp90 inhibitors is a property of disruption of
the WD repeat region [58]. Models of EML4-ALK fusion
protein variants based on the crystal structure of the
equivalent region from EML1 provided a structural
explanation for these observations [18]. In variants that are
more sensitive to Hsp90 inhibition, such as v1 and v2, the
fusion breakpoint disrupts the TAPE domain, resulting in a
protein with insufficient number of WD repeats to form
complete propeller structures. These proteins are highly
unstable and dependent on Hsp90. Variants such as v3 and
v5, which lack the TAPE domain entirely, are independent
of Hsp90. H3122 cells harbouring v1 are more sensitive to
the Hsp90 inhibitor ganetespib than H2228 cells harbour-
ing v3, and a similar observation has been made using
17-DMAG [18, 104]. It is important to establish whether
the difference in Hsp90 inhibitor sensitivity observed
in vitro is a factor in the response of patients to these
Table 2 Drug sensitivity or resistance to ALK mutations
ALK inhibitor Crizotinib Ceretinib Alectinib PF-06463922
Resistance mutation
G1123S Resistant [113] Sensitive [113]
1151Tins Resistant [79, 90] Resistant [90] Resistant [79] Sensitive [87]
L1152P/R Resistant [90] Resistant [90] Sensitive [114] Sensitive [87]
C1156Y/T Resistant [90] Resistant [90] Sensitive [87] Sensitive [87]
I1171T/N Resistant [90] Sensitive [90, 115, 116] Resistant [115, 116] Sensitive [87]
F1174L/C Resistant [90] Resistant [90] Sensitive [115] Sensitive [87]
V1180L Resistant [115] Sensitive [115] Resistant [115] Sensitive [87]
L1196M Resistant [78, 79, 83] Sensitive [90] Sensitive [87] Sensitive [87]
G1202R Resistant [79, 90] Resistant [84, 90] Resistant [79] Sensitive [72, 87]
S1206Y Resistant [79, 90] Sensitive [90] Sensitive [79] Sensitive [87]
G1269A/S Resistant [90] Sensitive [90] Sensitive [114] Sensitive [87]
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inhibitors so that informed decisions can be made regard-
ing the most effective treatment strategy for patients with
tumours harbouring the different EML4-ALK fusion
variants.
Because they act through a different mechanism, Hsp90
inhibitors also induce the degradation of ALK fusion pro-
teins that are resistant to ALK inhibitors. For example,
ganetespib is equally potent against 15 different drug-re-
sistant mutants of NPM-ALK fusions as wild-type NPM-
ALK [103]. Furthermore, Hsp90 inhibitors do not just
deplete EML4-ALK, and their ability to block multiple
oncogenic pathways may be advantageous in patient
treatment. Several oncogenic RTKs are Hsp90 clients, and
Hsp90 inhibitors could prevent drug resistance arising
through bypass pathways mediated by these RTKs. For
example, EGFR and MET activation by addition of ligands
induces resistance to alectinib in H2228 cells, which can be
overcome with Hsp90 inhibition [104]. Resistance to
Hsp90 inhibitors could be mediated through upregulation
of other heat shock proteins, such as Hsp70, or through
alterations in apoptotic signalling pathways, and it remains
to be seen which mechanisms contribute in NSCLC
patients [105, 106]. Hsp90 inhibitors may therefore be
particularly useful in the treatment of NSCLC patients who
have developed resistance to ALK inhibitors, or perhaps as
a first-line therapy in combination with ALK inhibitors.
Combinations of ALK and inhibitors of other RTKs
or Hsp90
Cytotoxic chemotherapy treatment is usually delivered as a
combination of drugs, which maximize cancer cell death
through additive effects or synergism between mechanisms
of action. By this rationale, it should be possible to find
combinations of ALK inhibitors with other therapeutics
that improve patient outcomes. There are many ways to
identify combinations of drugs, starting from a rational
basis or through screening approaches.
Synergy between ALK and Hsp90 inhibitors has been
shown in Ba/F3 cells, but was dependent on the EML4-
ALK fusion variant with v1 showing the least effect [58].
The combination of crizotinib and ganetespib showed
enhanced cell death of H3122 cells in culture, and the
combination reduced tumour growth by over 90 % in mice
bearing H3122 xenografts [103]. Clinical trials of ALK and
Hsp90 inhibitors in combination are underway.
Insulin-like growth factor 1 receptor (IGF-1R) was
identified as a potential target for combinatorial drug
treatment of EML4-ALK NSCLC, based on the excep-
tional response of a patient to IGF-1R mAb plus erlotinib
and an in-depth study of EML4-ALK cell lines [55]. The
patient’s tumour was not molecularly profiled until she
progressed on this treatment, when an ALK rearrangement
was identified and she was treated with crizotinib. Inhibi-
tion of ALK using crizotinib and IGF-1R was synergistic in
EML4-ALK model cell lines (H2228, H3122 and STE-1),
and in crizotinib-resistant cell lines based on H3122. IGF-
1R pathway activity was increased in crizotinib-resistant
cell lines. Interestingly, the authors of this study noted that
the LDK-378 ALK inhibitor also inhibits IGF-1R, which
may in part explain the high response rate to this drug of
patients who have progressed on crizotinib [55].
Several signalling pathways are activated in EML4-
ALK cells, and dual targeting of ALK with these other
pathways may be beneficial, particularly in pathways that
are not entirely blocked by ALK inhibition. For example,
treatment of H2228 cells with TAE684 does not markedly
affect phosphorylation of ERK at concentrations at which
ALK phosphorylation is inhibited [56, 61]. Indeed, a
combination of ALK and MEK inhibitors substantially
increases apoptosis in H2228 cells [61].
A recent paper provides evidence that upfront dual
inhibition of ALK and MEK may be advantageous, at least
in some EML4-ALK patients [62]. Cell growth of H3122
or STE-1 cells was decreased by inhibition of ALK or
MEK, but not inhibition of AKT or PI3 K. Lung cancer
cell lines harbouring K-RAS or BRAF mutations, but not
EGFR, were also sensitive to MEK inhibition. Activation
occurs at the level of RAS because GTP loading of N-RAS,
H-RAS and K-RAS were all enhanced by EML4-ALK in
H3122 or STE-1 cells. The mechanism of RAS activation
by EML4-ALK is unclear because the fusion protein does
not localise to the plasma membrane. Intriguingly, RAS
activation appears to be dependent on the HELP motif of
EML4-ALK v1. This implies that EML4-ALK variants
lacking the HELP motif, such as v3 and v5, may have
different downstream signalling, perhaps as a consequence
of their association with distinct complexes and alternative
subcellular localisations.
The combination of ALK and MEK inhibitors was also
effective in a ceritinib-resistant cell line derived from a
patient and, in this case, the effectiveness of the combi-
nation may have been due to the presence of an activating
mutation in MAP2K1 [81]. However, in this study, there
was no advantage to combining the two inhibitors in other
cell lines. In contrast, a different study suggests that a high
proportion of the bypass resistance mechanisms in response
to ALK inhibition involve activation of MAPK signalling
[82]. There are several other candidate kinase targets for
co-inhibition alongside ALK, including SRC, ERBB2/
HER2 and PKC [51, 81, 82]. It is not yet clear which
combinations of kinase inhibitors should be prioritized for
clinical studies and how patients should be selected for
these trials.
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Conclusions
The identification of the EML4-ALK fusion in a subset of
NSCLC patients, and the response of these patients to
crizotinib is a clear example of the value of molecular
genetics aligned with targeted approaches to cancer drug
discovery. The ability of researchers to develop second-
generation ALK inhibitors that have substantially improved
pharmacological properties is a testament to the power of
medicinal chemistry, backed by rational drug design
approaches. However, as exciting as these advances are, we
are still a long way from being able to offer patients a
programme of treatments that cures their disease, or at least
keeps it at bay for a decade or more. Therefore, the key
challenge ahead is to identify rational combinations of
drugs based on molecular and genetic analysis of an indi-
viduals tumour that prolong the duration of response to
treatment, and to identify appropriate strategies to over-
come resistance. Here we have described the current state of
the art, from which improved programmes of treatment will
develop. We believe that the answers to the following
questions will be critical if we are to achieve dramatically
improved patient outcomes:
What are the missing connections in the signalling
pathways that connect EML4-ALK to cancer proliferation
and survival, and how can we exploit these in therapy?
Over the next few years, we will discover much more about
this intriguing oncoprotein and how the combination of
different portions of EML4 and ALK affect its behaviour.
In particular, we will learn much about the signalling
pathways and mechanisms of resistance from clinical
studies on second-generation ALK inhibitors alone and in
combination with other therapeutics.
What is the best strategy for ALK inhibitors in the
clinic? Second-generation ALK inhibitors show benefit in
patients who have relapsed on crizotinib, and have been
approved by the FDA for treatment of these patients. We
do not yet know which of them are the preferred options in
crizotinib-resistant patients and whether, in time, they
ought to replace crizotinib as the first-line therapy.
Do we need to develop further ALK inhibitors, and what
properties should they have? Unfortunately, drug resis-
tance to advanced ALK inihibitors is inevitable. Because
these inhibitors are more potent against ALK, and retain
effective potency against key ALK mutants, we would
expect a higher proportion of mutations that activate
bypass pathways versus further mutations in ALK or ALK
overexpression. In this context, the off-target effects of
crizotonib, such as inhibition of MET, AXL and RON, may
be beneficial in preventing the activation of bypass resis-
tance pathways [82]. In considering the development of
further ALK inhibitors to fully address drug resistance
mechanisms, activity against selected other kinases may be
a desirable property, as well as activity against key drug-
resistance mutations in ALK.
How are bypass pathways selected for during ALK
inhibitor treatment, can we predict which path of drug
resistance a tumour is likely to exploit, and how do we
target these pathways on an individual patient basis? Ini-
tial studies suggested a number of bypass pathways, and we
have to build a clear picture of the overall signalling net-
work. Addressing this, for example through next generation
sequencing, will require significant effort over the next few
years as clinical samples of patients treated with second-
generation ALK inhibitors become available.
Which therapeutics should be used in addition to ALK
inhibitors and how? There are many suggestions for ther-
apeutics that could be used following ALK inhibitory
therapy, or perhaps in combination. These include Hsp90
inhibitors and inhibitors of other RTKs. It is also possible
that cancer immunotherapies will form part of the treat-
ment programme [107].
How is the EML4 part of the fusion significant? In our
view, the presence of a misfolded, partial TAPE domain in
most EML4-ALK variants is a defining feature of these
oncoproteins. This feature underlies exquisite sensitivity to
Hsp90 inhibitors and the exposure of the HELP motif
promotes RAS signalling. While EML4-ALK v3 localises
to microtubules, the presence of a partial TAPE domain in
other variants prevents microtubule association and may
confer localisation to discrete cytoplasmic structures. This
may contribute to oncogenic signalling by promoting co-
localisation with other signalling molecules. Further work
is required to elaborate the contribution of the EML4
portion of the fusion protein and exploit this in the clinic.
Will the treatment of EML4-ALK patients be stratified by
variant type? EML4-ALK variants are inhibited differently
by ALK and Hsp90 inhibitors in vitro, but it remains to be
seen whether these differences will be observed in the
clinic. However, given the gross differences in the molec-
ular properties of some variants, such as v3 or v5 compared
with the others, it seems likely that some differences will be
observed in patient response and drug resistance mecha-
nisms. Most patients harbour one of the three most common
variants and, provided that the variant is determined during
clinical trials, it will be possible to identify any differences
of clinical significance. However, it will be difficult to
obtain sufficient data for the rare variants and we believe
that it is crucial to develop models that provide a rational
basis for planning the treatment of these patients.
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